Sequence variants affecting blood lipids and coronary artery disease (CAD) may enhance understanding of the atherogenicity of lipid fractions. Using a large resource of whole-genome sequence data, we examined rare and low-frequency variants for association with non-HDL cholesterol, HDL cholesterol, LDL cholesterol, and triglycerides in up to 119,146 Icelanders. We discovered 13 variants with large effects (within ANGPTL3, APOB, ABCA1, NR1H3, APOA1, LIPC, CETP, LDLR, and APOC1) and replicated 14 variants. Five variants within PCSK9, APOA1, ANGPTL4, and LDLR associate with CAD (33,090 cases and 236,254 controls). We used genetic risk scores for the lipid fractions to examine their causal relationship with CAD. The non-HDL cholesterol genetic risk score associates most strongly with CAD (P = 2.7 × 10(-28)), and no other genetic risk score associates with CAD after accounting for non-HDL cholesterol. The genetic risk score for non-HDL cholesterol confers CAD risk beyond that of LDL cholesterol (P = 5.5 × 10(-8)), suggesting that targeting atherogenic remnant cholesterol may reduce cardiovascular risk.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9136713 | PMC |
| http://dx.doi.org/10.1038/ng.3561 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Metabolic factors modulate effort-based decision-making in major depressive disorder.
J Affect Disord
December 2024
Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada; Institute of Medical Science, University of Toronto, Toronto, ON, Canada; Department of Psychiatry, University of Toronto, Toronto, ON, Canada. Electronic address:
Background: Abnormalities in effort-based decision-making have been consistently reported in major depressive disorder (MDD). Evidence indicates that metabolic factors, such as insulin resistance and dyslipidemia, which are highly prevalent in MDD, are independently associated with reward disturbances. Herein, we investigate the moderating effect of metabolic factors on effort-based decision-making in individuals with MDD.
View Article and Find Full Text PDFTracking of serum lipids from prepuberty to young adulthood: results from the KiGGS cohort study.
Lipids Health Dis
December 2024
Department of Epidemiology and Health Monitoring, Robert Koch-Institute Berlin, Berlin, Germany.
Background: Universal lipid screening in childhood for early detection and treatment of familial hypercholesterolemia is under discussion, but will also detect children with multifactorial dyslipidemia. Results from population-based studies can support the design of public health strategies. As few previous studies considered pubertal changes in serum lipid levels, we examined tracking of serum lipids from prepuberty to young adulthood in a population-based cohort.
View Article and Find Full Text PDFLevothyroxine therapy reduces endocan and total cholesterol concentrations in patients with subclinical hypothyroidism.
Biochem Med (Zagreb)
February 2025
Department of Medical Biochemistry and Hematology, Faculty of Pharmacy and Biochemistry, University of Zagreb, Zagreb, Croatia.
Introduction: Subclinical hypothyroidism (SCH) is an independent risk factor for cardiovascular diseases due to endothelial dysfunction and atherosclerosis development. The aim of this study was to determine whether the levothyroxine therapy could impact the concentrations of endothelial dysfunction blood markers, namely endothelin-1 (ET-1), asymmetric dimethylarginine (ADMA) and endocan, in patients with a mild form of SCH (thyroid-stimulating hormone (TSH) ≤ 10 mIU/L).
Materials And Methods: In this case-control prospective study, SCH patients and healthy controls were recruited during their regular health examinations.
The role of serum biomarkers in determining systemic inflammation and cardiovascular risk in pseudoexfoliation syndrome.
Int Ophthalmol
December 2024
Department of Ophthalmology, Beypazari State Hospital, Ankara, Turkey.
Purpose: To investigate the role of hematological and atherogenic biomarkers in evaluating systemic inflammation and cardiovascular risk in patients with pseudoexfoliation syndrome.
Methods: This retrospective study included 200 patients, 90 with pseudoexfoliation (PEX) syndrome (Group 1) and 110 healthy controls (Group 2). Twelve-hour fasting blood samples were collected to measure complete blood count, neutrophil/lymphocyte ratio (NLR), monocyte/lymphocyte ratio (MLR), platelet/lymphocyte ratio (PLR), systemic immune-inflammation index (SII) (neutrophil x platelet/lymphocyte), systemic inflammatory response index (SIRI) (neutrophil x monocyte/lymphocyte), pan-immune inflammation value (PIV) (neutrophil x platelet x monocyte/lymphocyte), C-reactive protein (CRP), uric acid, glucose, triglycerides (TG), total cholesterol, HDL, LDL, non-HDL, and triglyceride-glucose (TyG) index (Ln (TG [mg/dL] × glucose [mg/dL]/2)).
Effects of Pemafibrate on LDL-C and Related Lipid Markers in Patients with MASLD: A Sub-Analysis of the PEMA-FL Study.
J Atheroscler Thromb
December 2024
Department of Cardiology, Rinku General Medical Center.
Aim: In the PEMA-FL study in patients with metabolic dysfunction-associated steatotic liver disease (MASLD), pemafibrate was shown to significantly decrease low-density lipoprotein cholesterol (LDL-C) levels. We aimed to investigate the mechanisms of pemafibrate-induced LDL-C reduction in patients with MASLD by conducting an additional sub-analysis of the PEMA-FL study.
Methods: The PEMA-FL study randomized 118 patients with MASLD to receive pemafibrate or placebo for 72 weeks.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!